The hedge fund Perigon Wealth Management in its last quarterly 13F reported a total value of its portfolio of $379 million, with an increase of 4.19% since the previous quarter. During Q2 2015, the firm bought eight new stocks and increased 100 of its existing stakes. The following are the most heavily weighted buys during the quarter.
It bought shares of Allergan PLC (AGN) with an impact of 1.63% on its portfolio. The company is engaged in development, manufacturing, marketing, sale and distribution of generic, branded generic, brand name, biosimilar and over-the-counter pharmaceutical products. It also develops and out-license generic pharmaceutical products in Europe through its Medis third-party business. It operates in three segments: Pharma, Specialty Brands and Anda Distribution. Continue Reading »